NOX 1.52% 6.7¢ noxopharm limited

Ann: Veyonda and Opdivo IONIC Study First Patient Dosed, page-12

  1. 424 Posts.
    lightbulb Created with Sketch. 206
    Bristol Myers adds to neoadjuvant win for Opdivo in lung cancer, escalating early cancer showdown with Merck – Endpoints News (endpts.com)

    NOX is a while off knowing if IONIC is a success but its nice to think about what would happen to the share price if Veyonda shows itself to be the catalyst for increased efficacy of PD-(L)1 inhibitors. What would BMS pay to get out well ahead of keytruda?
    Last edited by couldwellb: 09/11/21
 
watchlist Created with Sketch. Add NOX (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.